ArticleAntimicrobial agents and chemotherapy2026
Analysis of interactions between posaconazole/voriconazole and venetoclax.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation.Molecular and cellular pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Venetoclax (VEN), a selective BCL-2 inhibitor predominantly metabolized by CYP3A4, is a cornerstone therapeutic for myeloid neoplasms (MNs). Patients with myeloid malignancies are at elevated risk of invasive fungal infections (IFIs), and triazole antifungal drugs, such as posaconazole (PCZ) and voriconazole (VCZ), are commonly used for prophylaxis or treatment. These agents are potent CYP3A4 inhibitors and will exhibit significant potential for pharmacokinetic drug-drug interactions with VEN. Although studies on their interaction are limited, such combinations are frequently used in clinical practice, making further research highly significant. This study aimed to investigate the changes in blood concentration and the safety of VEN when combined with triazole antifungal drugs (PCZ and VCZ). Patients with MN treated with VEN from April 2023 to April 2025 were enrolled and allocated to the VEN monotherapy group and the VEN plus triazole antifungal drug group. We collected baseline demographic characteristics and monitored adverse events. Steady-state plasma concentrations of VEN were quantified using the liquid chromatography-mass spectrometry methodology. Statistical analyses, including comparative assessments of plasma concentrations and adverse event rates, were performed using IBM SPSS Statistics 26. A total of 54 patients were enrolled in the study. Following VEN dose reduction to 100 mg, plasma concentrations in the VEN + PCZ/VCZ group remained significantly elevated compared to the VEN group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.